Fetal Cell Isolation Using Fetal Membrane Markers

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for isolating fetal cells from maternal blood are laborious and limited to a narrow time frame, typically around 12 weeks of gestation, making them less effective for prenatal testing beyond this period.

Innovation Solution

The method involves using ligands directed against markers of fetal membrane cells to isolate these cells from maternal blood samples, which are shed in higher numbers during the expansion of fetal membranes between weeks 15-20 of gestation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If common isolation methods (MACS, FACS) are used to isolate fetal cells, then fetal cells can be isolated with high precision, but the isolation is limited to a narrow time frame around 12 weeks of gestation

Engineering Contradiction:
Improveisolation precisionVSAvoidisolation time frame
Core Design Contradiction:
Measurement precisionVSDuration of action of moving object

Solution Approach 1:

The patent changes the target parameter from placenta-derived fetal cells to fetal membrane cells, which are shed in higher numbers during membrane expansion (weeks 15-20). This parameter change in cell source and timing enables isolation beyond the narrow 12-week window while maintaining isolation precision through specific markers like cytokeratins and vimentin

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent performs preliminary enrichment of fetal cells before final isolation using specific markers. This preliminary action increases the concentration of fetal membrane cells in the sample, making subsequent detection and isolation more effective during the extended gestational period

Inventive Principle:
Principle #10Preliminary action

2Reliability

If placenta-derived fetal cells are used for isolation, then prenatal testing can be performed, but the numbers of cells drop after 12 weeks making isolation difficult

Engineering Contradiction:
Improveprenatal testing reliabilityVSAvoidfetal cell numbers
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The patent extracts and isolates fetal membrane cells from maternal blood using specific markers (cytokeratins, vimentin) that are uniquely expressed on these cells. This extraction method targets a different cell population (fetal membrane cells instead of placenta-derived cells) that remains abundant during weeks 15-20, maintaining both reliability and quantity for prenatal testing

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses specific markers (cytokeratins, vimentin) as intermediaries to identify and isolate fetal membrane cells. These markers serve as mediators that enable reliable detection and separation of fetal cells from maternal blood during the gestational period when fetal membrane cells are naturally abundant

Inventive Principle:
Principle #24Intermediary (Mediator)

3Reliability

If fetal cells are isolated using traditional methods, then diagnosis can be performed, but the process is laborious and time-consuming

Engineering Contradiction:
Improvediagnostic accuracyVSAvoidisolation time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent changes the cell target parameter to fetal membrane cells which are naturally more abundant during weeks 15-20, reducing the time and effort required for isolation. The use of specific markers enables more efficient enrichment and isolation compared to traditional methods, maintaining diagnostic accuracy while reducing procedural time

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for the isolation of fetal cells over a longer period than traditional methods, enhancing the utility of fetal cells in prenatal diagnostics.

Implementation Method 1

contacting the cells comprised in the maternal blood sample with a ligand directed against a fetal membrane cell marker

Methodology Applied
Scientific EffectAntigen-antibody binding:

Implementation Method 2

One such method of enrichment is based on Magnetic Activated Cell Sorting (MACS) where antibodies conjugated to magnetic beads are used to target fetal cells

Methodology Applied
Scientific EffectMagnetic separation: Magnetism

Implementation Method 3

After enrichment, fetal cells are stained with specific antibodies and identified and isolated using different technologies, including fluorescence scanner integrated with a microscope

Methodology Applied
Scientific EffectFluorescence: Fluorescence

Data Source

PatentUS20250027940A1Isolation and Diagnostics of Fetal Cells
Publication Date: 2025.01.23 ARCEDI BIOTECH APS

AI summary

The present disclosure relates to methods of fetal cell isolation and methods of prenatal diagnostics. The disclosure furthermore provides novel markers for fetal cell isolation that can be used to isolate fetal cells for prenatal diagnostics.